Cyclerion Therapeutics Inc (NASDAQ:CYCN) insider Andreas Busch bought 125,000 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was bought at an average price of $1.82 per share, for a total transaction of $227,500.00. Following the transaction, the insider now owns 125,000 shares of the company’s stock, valued at $227,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of NASDAQ CYCN traded up $0.02 during trading on Tuesday, hitting $1.82. The company had a trading volume of 926,600 shares, compared to its average volume of 1,044,097. Cyclerion Therapeutics Inc has a fifty-two week low of $1.69 and a fifty-two week high of $21.00. The stock has a fifty day simple moving average of $7.05 and a two-hundred day simple moving average of $10.55. The company has a quick ratio of 6.32, a current ratio of 6.32 and a debt-to-equity ratio of 0.60.

A number of hedge funds and other institutional investors have recently modified their holdings of CYCN. Russell Investments Group Ltd. acquired a new stake in Cyclerion Therapeutics in the 3rd quarter valued at about $1,112,000. First Trust Advisors LP acquired a new stake in Cyclerion Therapeutics in the 3rd quarter valued at about $430,000. California Public Employees Retirement System acquired a new stake in Cyclerion Therapeutics in the 3rd quarter valued at about $404,000. Finally, Broderick Brian C acquired a new stake in Cyclerion Therapeutics in the 3rd quarter valued at about $399,000. 72.16% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

There is no company description available for Cyclerion Therapeutics Inc

See Also: What is the G-20?

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.